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Abstract: Novel boron-rich, carboranyl–indole carboxamide
ligands were prepared and found to effectively target the
18 kDa translocator protein (TSPO), an upregulated mito-
chondrial membrane-bound protein which has been ob-
served in variety of tumor cell lines and its expression ap-
pears to be proportional to the degree of tumorigenicity,
emphasizing a key role in cancer cell proliferation. Both
boronated compounds displayed remarkably high affinities
for the TSPO. In addition, the in vitro uptake of these com-
pounds into T98G human glioma cells was found to be 25-
to 100-fold greater than that of clinical boron neutron cap-
ture therapy (BNCT) agents.
Introduction
An ideal anti-cancer therapy would show high selectivity and
toxicity for cancer cells only, thus leaving surrounding healthy
tissue unaffected by treatment. Given the raft of side-effects
associated with modern chemotherapeutic and/or radiothera-
peutic regimens, achieving high selectivity and toxicity toward
tumor cells with minimal ill effects towards normal, healthy
cells remains an elusive goal in cancer therapy. Boron neutron
capture therapy (BNCT) is an experimental cancer treatment
designed to take advantage of the physicochemical properties
of molecular agents containing the non-radioactive 10B isotope
(19.8% natural abundance) in a binary therapy incorporating
the delivery of boron compounds to the cancer site and subse-
quent targeted irradiation of the tumour mass with low energy
(ca. 0.025 eV) thermal neutrons. Neutron capture by the 10B nu-
cleus results in a series of fission events that generate high
linear energy transfer (LET) alpha particles (4He2+) and recoiling
lithium-7 (7Li3+) nuclei. LET particles can travel approximately
5–9 mm in tissue, which is comparable to the size of a typical
mammalian cell. Thus, high-energy LET particles produce de-
structive cellular effects that are limited to those boron-con-
taining cells irradiated by thermal neutrons.[1] In principle, the
targeted selectivity and toxicity of BNCT for malignant cells
over neighboring normal cells provides a viable pathway in
achieving high selectivity in tumor cell kill as long as suitable
tumor-selective boronated compounds are used. Such agents
require favorable physiological properties in order to act suc-
cessfully as a useful anti-cancer therapy. Briefly, these features
include: high uptake of boron into tumor cells (&20 mg 10B/g
tumour, or ca. 109 10B nuclei per cell), persistence of 10B within
the tumor during thermal neutron irradiation, and rapid clear-
ance of the 10B agent from the circulation and normal tissue.
Clinically, BNCT has been focussed on the experimental treat-
ment of high-grade gliomas, recurrent tumors of head and
neck, melanoma, hepatic metastasis and mesothelioma. Cur-
rently, BNCT agents undergoing human trials include the
boron-containing amino acid (L)-4-dihydroxyborylphenylala-
nine (BPA, 1) and sodium mercaptoundecahydro-closo-dodeca-
borate (BSH, 2), both of which have demonstrated only
modest successes over the past few decades, particularly
against the aggressive and intractable malignant brain tumor
glioblastoma multiforme (GBM).[2]
The boron-rich cluster, dicarba-closo-dodecaborane (com-
monly known as closo-carborane) possesses pseudoaromatic
character afforded by the cluster’s intrinsic s-electron delocali-
zation. Carboranes exhibit low toxicity in vivo, are kinetically
stable to metabolic degradation, and can improve drug bio-
availability when utilized as a unique scaffold in medicinal
chemistry.[3] Moreover, the incorporation of closo-carborane
cage within a BNCT agent may allow greater boron loading ca-
pacity than single-boron agents such as BPA given the carbor-
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ane moiety contains 10 boron atoms per cluster. It has been
shown that carborane-containing molecules can bind specifi-
cally to protein receptors overexpressed in tumor cells such as
PSMA, EGFR, 5-lipoxygenase, and the folate receptor,[4] thus
once an appropriate tumor target has been selected, carbor-
ane-containing molecules represent a practical method for en-
hanced boron delivery to tumor cells.[5, 6]
The 18 kDa translocator protein (TSPO) is a five transmem-
brane-domain protein consisting of 169 amino acid residues.
Formerly known as the peripheral benzodiazepine receptor
(PBR), it is chiefly localized at the contact sites between the
outer and the inner mitochondrial membranes of steroid-pro-
ducing cells and various other tissues.[7] TSPO is associated
with specific mitochondrial proteins such as the voltage-de-
pendent anion channel (VDAC) and adenine nucleotide trans-
porter (ANT), and is implicated in the regulation of the open-
ing of the mitochondrial permeability transition pore (MPTP).
TSPO has been shown to play a role in various physiological
functions, including cholesterol transport, steroidogenesis, cal-
cium homeostasis, lipid metabolism, mitochondrial oxidation,
cell growth and differentiation, apoptosis induction, MPTP
opening, and regulation of immune functions.[7–10] Importantly,
TSPO upregulation has been observed in variety of tumor cell
lines and its expression appears proportional to the degree of
tumorigenicity, emphasizing a key role in cancer cell prolifera-
tion which makes TSPO an attractive target for cancer thera-
py.[11–15]
PK11195 (3) is a widely-used ligand for TSPO studies
(Figure 1). Despite having high affinity towards TSPO, PK11195
displays non-specific binding, variable kinetic behavior and low
bioavailability. Several PK11195-derived carborane analogs
were synthesized and probed for their potential to deliver
boron in tumour cells and application towards BNCT.[16] Howev-
er, the tumor cell line (breast cancer) utilized in those experi-
ments are not amenable to current BNCT therapy, which fo-
cusses on cranial/extra-cranial tumors. Previously, we have re-
ported that pyrazolopyrimidine-containing carborane com-
pounds represent a new class of boronated agents that can ef-
fectively target the TSPO.[3] We observed that in vitro uptake of
the carboranyl derivatives 4 and 5 into T98G human glioma
cells was significantly higher than clinical agents currently used
in BNCT. Compound 4 (19.75:1.13 mg Bmg@1 protein) was
found to deliver one order of magnitude greater amount of
boron into T98G cells than either BSH (1.49:0.26 mg Bmg@1
protein) or the BPA-fructose adduct (BPA-fr) (1.38:0.24 mg
Bmg@1 protein). Moreover, the in vitro cytotoxicities of 4 and 5
were found to be low with CC50=219.7:35.9 mM and 220.9:
40.3 mM, respectively, against the T98G human glioma cell line.
We also observed that conversion of closo-1,2-carborane 4 to
the anionic nido-7,8-carborane 5 resulted in a slight loss of
binding affinity, as well as a reduction in boron uptake of
tumor cells.[3]
In our quest for highly selective, boron-rich, high-affinity li-
gands for TSPO with low cytotoxicity and an ability to deliver
high concentrations of boron to cancer cells, we designed a
series of novel carborane-containing indole-based ligands for
the TSPO. Recently, a three-dimensional high-resolution struc-
ture of mammalian TSPO reconstituted in detergent micelles
associated with its high-affinity ligand PK11195 has been re-
ported.[17] The new ligands reported here are based on the
ligand-based structure activity relationship (SAR) data of
known TSPO ligands and a known pharmacophore model
(Figure 2).[7, 18] Herein we report the synthesis of two novel car-
boranyl-indole carboxamides, their affinity for the TSPO, and
biological evaluation which specifically entails a study of their
capacity to deliver high concentrations of boron in T98G
human glioma cells in the absence of thermal neutrons.
Results and Discussion
The synthesis of carboranyl indole 3-carboxamide was com-
menced from the commercially available 6-chloroindole, as
shown in Scheme 1. N-alkylation of indole 6 was achieved
using sodium hydride (NaH) and N,N-diethylchloroacetamide in
DMF followed by addition of trifluoroacetic anhydride to afford
3-trifluoroacetyl indole 7. Basic hydrolysis of trifluoromethyl
ketone furnished acid 8 which upon treatment with oxalyl
chloride generated the acid chloride derivative, which was fol-
lowed by amidation with N-methylpropargylamine to yield
Figure 1. Chemical structures of BNCT agents 1 and 2, PK11195 (3), and pre-
viously-reported boronated TSPO ligands 4 and 5.
Figure 2. Design of TSPO ligands. As per the TSPO pharmacophore
model:[7,18] pocket L1 is occupied by ring A, pocket L3 is occupied by ring B
and pocket L4 is occupied by alkyl substituents on the amide nitrogen. H-
bond donor group of the amide carbonyl is crucial for the activity and any
functional modification results in the loss of activity.
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indole 3-carboxamide 9. Closo-1,2-carboranyl indole 10 was
prepared by the reaction of 9 with the decaborane-acetonitrile
adduct (prepared in situ from nido-decaborane and CH3CN)
under reflux conditions. Purification by means of silica column
chromatography gave the desired 10 as a pale-yellow solid.
The synthetic route for carboranyl indole 2-carboxamide
(Scheme 2) began with commercially-available 3,5-dichloro-
phenyl hydrazine hydrochloride 11 which was converted to hy-
drazone using ethyl pyruvate under reflux conditions, followed
by the Fischer indole cyclization using polyphosphoric acid at
120 8C to give indole ester 12. N-benzylation of indole ester 12
occurred upon treatment with NaH and PMB-chloride to pro-
vide ester 13. Basic hydrolysis of 13 under reflux conditions
gave the corresponding acid, which was converted to the acid
chloride using oxalyl chloride. This was followed by amidation
with commercially available N-methylpropargylamine to pro-
vide the indole carboxamide 14. Closo-1,2-carboranyl indole 15
was obtained by reaction of propargyl amide 14 with decabor-
ane-acetonitrile adduct under reflux conditions to yield carbor-
anyl indole 2-carboxamide 15 as an off-white solid.
The structures of both 10 and 15 were confirmed by multi-
nuclear (1H, 13C and 11B) NMR spectroscopy and high-resolution
ESI-MS, and their purity was confirmed by HPLC prior to bio-
logical evaluation. In the 13C{1H} NMR spectrum of 10, the reso-
nances at 75.2 and 61.1 ppm are attributed to the two carbor-
ane cluster carbon atoms. Similarly, 13C{1H} NMR spectrum of
15 displayed resonances at 73.7 and 60.3 ppm. Compounds 10
and 15 exhibit five unique boron atom environments between
@1 to @13 ppm in their 11B{1H} NMR spectra, indicating the
presence of an intact closo-1,2-carborane moiety.
Having confirmed their molecular structures, boron-rich
indole carboxamides 10 and 15 were then assessed for their
ability to bind TSPO in a competitive membrane binding assay
using [3H]-PK11195 as a radioligand using mitochondrial frac-
tions isolated from the rat kidney as the receptor source. Both
compounds competitively inhibited the binding of [3H]-
PK11195 and displayed high affinity for TSPO. Compounds 10
and 15 competitively inhibited the binding of [3H]-PK11195
with an affinity of 0.49:0.05 nm and 294.5:30.0 nm, respec-
tively. Unlike compound 4, which revealed a unique two-site
binding configuration (a high-affinity and a low-affinity binding
site), the displacement of [3H]-PK11195 by compounds 10 and
15 was best fit to a one-site model. The binding affinity of
compound 15 is in accordance with the previously-reported
carboranyl TSPO ligands.[3, 16] However, compound 10 with a
Ki=0.49:0.05 nm displays the highest TSPO affinity of a
boron-containing ligand reported to date.
Low cytotoxicity of boronated agents is a pivotal parameter
for BNCT that allows for high boron levels to be accumulated
within the tumor. Compounds 10 and 15 displayed no discern-
ible in vitro cytotoxicity at concentrations of 100 mM against
T98G human glioma cells, a clinically-amenable tumour cell
line for BNCT, or SVGp12 human glial cells. When compared to
the lipophilic phosphonium-carborane ligands, closo-1,2-car-
boran-1-ylmethyl)triphenylphosphonium bromide (CC50=of
21.1:1.4 mM) and 7,8-dicarba-nido-undecaborane-7-ylmethyl)-
triphenylphosphonium (CC50=60.6:19.0 mM) which contain a
closo- and nido-carborane cage, respectively, compounds 10
and 15 display far less cytotoxicity against the same cancer cell
line.[19] PK11195-derived closo-carboranyl ligands have also
been reported to display higher cytotoxicity (CC50=116.0:
4.1 mm) against breast tumor cell lines.[16]
Cellular accumulation studies of 10 and 15 within cultured
T98G cells were conducted in order to determine the boron
Scheme 1. Synthetic route to carboranyl indole 3-carboxamides. Reagents
and conditions: (a) 1. NaH, N,N-diethyl chloroacetamide, 0 8C to RT, 1 h 2. Tri-
fluoroacetic anhydride, 0 8C, 2 h, quantitative; (b) KOH, EtOH:H2O, reflux, 4 h,
70%; (c) 1. Oxalyl chloride, CH2Cl2, RT, 2 h (d) N-Methylpropargylamine, Et3N,
CH2Cl2, 0 8C to RT, 2 h, 75%; (e) nido-decaborane, CH3CN, toluene, reflux,
24 h, 35%.
Scheme 2. Synthetic route to carboranyl indole 2-carboxamides. Reagents
and conditions: (a) 1. AcONa, EtOH, reflux, 2 h 2. PPA, 120 8C, 30 min, 70%;
(b) NaH, 4-methoxybenzyl chloride, DMF, 0 8C to RT, overnight, 81%; (c) KOH,
EtOH:H2O, reflux, 2–8 h, 91%; (d) 1. Oxalyl chloride, CH2Cl2, RT, 2 h 2. N-
methylpropargyl amine, Et3N, CH2Cl2, 0 8C to RT, 75%; (e) nido-decaborane,
CH3CN, toluene, reflux, 24 h, 27%.
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delivery characteristics of these novel compounds within
human glioma cells (Figure 3). T98G cells were treated with 10
and 15 for 72 h at concentrations of 100 mM, followed by de-
termination of boron levels by means of inductively-coupled
plasma optical emission spectroscopy (ICP-OES). Com-
pounds 10 and 15 exhibited remarkably greater boron uptake
in T98G cells when compared to clinical BNCT agents 1 and 2.
Compound 10 (38.18 mg Bmg@1 protein) was found to deliver
a 25-fold greater amount of boron into T98G cells than either
BSH 2 (1.49:0.26 mg Bmg@1 protein) or BPA 1 (1.38:0.24 mg
Bmg@1 protein). Similarly, when compared to 4 (19.75:1.13 mg
Bmg@1 protein) and 5 (11.28:0.28 mg Bmg@1 protein), com-
pound 10 delivered higher amounts (two to four-fold, respec-
tively) of boron to T98G cells. Furthermore, compound 15
(141.86 mg Bmg@1 protein) delivered remarkably high amounts
of boron into T98G cells, with boron levels determined to be
two orders of magnitude greater than that of the clinical BNCT
agents 1 and 2. For comparison, lower levels of boron were
found for 10 (3.12:0.19 mg Bmg@1 protein) and 15 (33.52 mg
:1.11 Bmg@1 protein) in normal glial cells (SVGp12), indicating
that high accumulation of these compounds in T98G cells is in-
consistent with a passive diffusion mechanism alone. Indeed,
the clinical BNCT agents 1 and 2 are transported into tumor
cells by an active l-amino-acid transport mechanism and pas-
sive diffusion, respectively, neither of which are likely to be
dominant in the case of 10 or 15.[1] In comparison with the
high-affinity TSPO ligands 4 and 5, compound 15 was found
to deliver even greater amount of boron (7- to 14-fold) into
T98G cells. Intracellular boron accumulation of species 10 and
15 was also found to exceed that of mitochondrially targeted
closo-carborane-phosphonium salts by 5- to 17-fold within the
same tumor cell line.[19]
Conclusions
Two novel boron-rich, carboranyl–indole carboxamide ligands
were synthesized and found to effectively target TSPO. Both
compounds (10 and 15) displayed very high affinities for the
TSPO with Ki values of 0.49:0.05 nm and 294.5:30.0 nm, re-
spectively. The in vitro uptake of 10 and 15 into T98G human
glioma cells was found to be 25- to 100-fold greater than clini-
cal BNCT agents 1 and 2, and also displayed 4- to 12-fold
greater boron uptake than that determined in a normal glial
cell line. Both compounds 10 and 15 were also found to be
significantly less toxic toward cultured T98G human glioma
cells and exhibited no discernible cytotoxicity up to 100 mM.
Carboranyl indole 15 had a lower binding affinity for TSPO
when compared to 10, however the cellular accumulation of
15 was found to be approximately four-fold higher. This result
is most likely attributed to the differences associated with
measuring TSPO binding affinities using rat kidney mitochon-
drial fractions versus cellular uptake using intact human tumor
cells. Furthermore, drug parameters such as lipophilicity are
unlikely to play a major role in the significant cellular uptake
of 10 and 15 into T98G cells by means of passive diffusion as
much lower levels of boron uptake were found in the normal
glial cell line. In conclusion, this particular study demonstrates
a significant advance in the development of tumor-cell target-
ed BNCT agents through the targeting of a key mitochondrial
receptor protein. In vivo studies involving thermal neutrons
are currently being planned and will be reported in due
course.
Experimental Section
Syntheses
General
All glass apparatus were oven-dried prior to use. All chemicals
used were purchased from Aldrich Chemical Co. Ltd. (St Louis, MO,
USA). All solvents were distilled by standard techniques prior to
use. Where stated, reactions were performed under an inert atmos-
phere of nitrogen using syringe-septum cap techniques or a
Schlenk manifold. 1H NMR spectra were recorded at 300 MHz and
400 MHz, 13C{1H} NMR spectra were recorded at 75 MHz and
125 MHz, and 11B{1H} NMR spectra were recorded at 128 MHz using
Bruker 300 and Bruker 500 spectrometers. Chemical shifts (d) are
quoted in parts per million (ppm). Tetramethylsilane (TMS) was
used as an internal reference for 1H and 13C{1H} NMR spectra and
BF3·OEt2 was used for
11B{1H} NMR spectra (0 ppm). All coupling
constants (J) are given in Hertz and the splitting patterns are de-
signed as follows: s (singlet), d (doublet), dd (doublet of doublets),
t (triplet), dt (doublet of triplets), q (quartet), and m (multiplet).
Low- and high-resolution electrospray ionization (ESI) MS was car-
ried out using a Bruker (USA) Daltronics BioApexII with a 7T super-
conducting magnet and an analytical ESI source. Thin-layer chro-
matography was performed using Merck aluminium backed plates,
precoated with silica (0.2 mm, 60F254), which were developed using
one of the following techniques: UV fluorescence (254 nm) and
iodine vapors. Flash chromatography was performed on silica gel
(Merck silica gel 60H, particle size 5–40 mm).
2-(6-chloro-3-(2,2,2-trifluoroacetyl)-1H-indol-1-yl)-
N,N-diethylacetamide (7)
To a stirred solution of 6-chloroindole 6 (1.0 g, 6.60 mmol) in DMF
(10 mL) was added sodium hydride (528 mg, 13.19 mmol) in por-
tions at 0 8C and the mixture was stirred at RT for 15 min. 2-Chloro-
N,N-diethylamide (0.952 mL, 6.93 mmol) was then added to the
mixture at 0 8C and it was stirred for 30 min. Trifluoroacetic anhy-
dride (1.11 mL, 7.92 mmol) was then added dropwise whilst main-
Figure 3. ICP-OES determination of boron levels in T98G human glioma cells
treated with 1, 2, 4, 5, 10 and 15.
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taining the temperature at 0 8C, and the mixture was stirred for
3 h. Upon completion (TLC), the reaction was then quenched with
a saturated solution of sodium carbonate in H2O (10 mL). The pre-
cipitate formed was filtered off and air-dried to afford 7 as a
creamy-brown solid in quantitative yield which was used in the
next step without any further purification. 1H NMR (300 MHz,
CDCl3): d=8.30 (d, J=8.7 Hz, 1H), 7.95 (d, J=1.5 Hz, 1H), 7.32 (dd,
J=8.6 Hz, J=1.7 Hz, 1H), 7.23 (d, J=1.5 Hz, 1H), 4.92 (s, 2H), 3.48–
3.39 (m, 4H), 1.33 (t, J=7.2 Hz, 3H), 1.17 ppm (t, J=7.1, 3H).
13C NMR (75 MHz, CDCl3): d=164.2, 139.7, 138.1, 131.1, 125.6,
124.9, 124.0, 110.5, 48.5, 41.9, 41.4, 14.8, 13.2 ppm.
6-chloro-1-(2-(diethylamino)-2-oxoethyl)-N-methyl-N-(prop-
2-ynyl)-1H-indole-3-carboxamide (9)
A suspension of 2-(6-chloro-3-(2,2,2-trifluoroacetyl)-1H-indol-1-yl)-
N,N-diethylacetamide 7 (1.0 g, 2.78 mmol) and KOH (156 mg,
2.78 mmol) were stirred and refluxed at 95 8C for 4 h in EtOH:H2O
(10 mL, 2:1 (v/v)). Upon completion (TLC), the mixture was cooled
to ambient temperature and the solvent was removed in vacuo.
The reaction mixture was diluted with water and extracted with
ethyl acetate. The aqueous layer was cooled to 0 8C and acidified
with hydrochloric acid (2m) to pH 2 to give an oily solid. This solid
was then extracted with ethyl acetate, washed with water, brine,
dried over anhydrous MgSO4 and rotary evaporated to afford the
corresponding carboxylic acid as a light brown solid which was
used in the next step without any further purification (533 mg,
70%). This product (400 mg, 1.30 mmol) was dissolved in dried di-
chloromethane (5 mL) at RT, and DMF (1 drop) was added while
stirring. To this solution was added oxalyl chloride (122 mL,
1.43 mmol) dropwise and the mixture stirred for 2 h. The reaction
mixture was then concentrated in vacuo. It was then dissolved in
dried dichloromethane (10 mL) and cooled to 0 8C. N-methylpro-
pargylamine (131 mL, 1.55 mmol) and Et3N (541 mL, 3.89 mmol)
were then added the reaction mixture was stirred at RT for 1 h.
Upon completion, the mixture was diluted with dichloromethane
(100 mL) and washed with water (100 mL). The aqueous layer was
extracted with dichloromethane (2V). Combined organic layer was
washed with water, brine, dried over anhydrous magnesium sul-
fate, and dried in vacuo. The crude product was then purified by
column chromatography (eluent: 15–50% ethyl acetate in n-
hexane) to afford the desired product as a pale-yellow solid
(257 mg, 55%). 1H NMR (300 MHz, CDCl3): d=7.81 (d, J=2.4 Hz,
1H), 7.36 (s, 1H), 7.15 (dd, J=8.7 Hz, J=1.8 Hz, 1H), 4.70 (s, 2H),
4.31 (d, J=2.4 Hz, 2H), 3.46–3.37 (m, 4H), 3.19 (s, 3H), 2.31 (t, J=
2.4 Hz, 1H), 1.23 (t, J=7.1 Hz, 3H), 1.12 ppm (t, J=7.2 Hz, 3H).
13C NMR (75 MHz, CDCl3): d=166.6, 165.4, 137.2, 132.1, 129.2,
125.9, 122.7, 122.2, 110.6, 109.8, 79.4, 72.8, 47.9, 41.8, 41.1, 14.7,
13.2 ppm.
6-chloro-1-(2-(diethylamino)-2-oxoethyl)-N-methyl-N-(closo-
1,2-carboran-1-ylmethyl) -1H-indole-3-carboxamide (10)
To a solution of nido-decaborane (42 mg, 0.342 mmol) and acetoni-
trile (0.146 mL, 2.787 mmol) in toluene (25 mL), was added 6-
chloro-1-(2-(diethylamino)-2-oxoethyl)-N-methyl-N-(prop-2-ynyl)-
1H-indole-3-carbox-amide 9 (100 mg, 0.279 mmol). The resulting
mixture was stirred under reflux overnight. The solvent was re-
moved under reduced pressure and the residual oil was purified
by column chromatography (n-hexane-EtOAc solvent gradient
system: 100% v/v n-hexane followed by 20% v/v EtOAc, Rf=0.5) to
give the product as an off-white solid (44 mg, 33%). 1H NMR
(300 MHz, CDCl3): d=7.80 (d, J=2.4 Hz, 1H), 7.43 (s, 1H), 7.20 (dd,
J=4.5 Hz, J=2.7 Hz, 1H), 4.84 (s, 2H), 4.42 (s, 2H), 3.45–3.38 (m,
4H), 3.32 (s, 3H), 2.90–1.70 (m, 10H), 1.30 (t, J=7.0 Hz, 3H),
1.15 ppm (t, J=7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3): d=166.3,
165.2, 137.5, 131.4, 129.1, 124.1, 121.5, 119.2, 109.6, 104.2, 75.2,
61.1, 47.9, 43.5 41.7, 41.1, 14.6, 13.1 ppm. 11B NMR (128 MHz,
CDCl3): d=@1.15 (1B), @5.11 (1B), @10.81 (2B), @12.16 ppm (6B).
ESI-MS [M+H]+ m/z 479.2 (calc. 479.1). Anal. Calcd. for
C19H32B10ClN3O2 : C 47.74, H 6.75, N 8.79. Found: C 47.51, H 7.11, N
9.07.
Ethyl 4,6-dichloro-1H-indole-2-carboxylate (12)
To a suspension of 3,5-dichlorophenyl hydrazine (1 g, 4.684 mmol)
in ethanol, sodium acetate (385 mg, 4.684 mmol) and ethyl pyru-
vate (0.52 mL, 4.684 mmol) were added and the mixture was re-
fluxed for 3 h. Upon completion, the mixture was filtered and the
residue was washed with hot ethanol (3V). The combined filtrates
were evaporated in vacuo to afford the hydrazone which was used
in the next step without further purification. Polyphosphoric acid
(2.7 mL) was added to the hydrazone and the resulting mixture
was heated at 120 8C for 45 min. Upon completion (TLC), the reac-
tion mixture was cooled to ambient temperature and then to 0 8C.
The mixture was diluted with water and the pH was adjusted to 10
using KOH. The precipitated solid was filtered off, washed with
water, n-hexane and air-dried to afford the desired product as
pale-yellow solid. The crude compound was crystallized from di-
chloromethane-hexane to afford the pure compound as a pale-
yellow, fluffy solid (1.05 g, 87%). 1H NMR (300 MHz, CDCl3): d=9.42
(brs, 1H), 7.35 (t, J=1.2 Hz, 1H), 7.29 (dd, J=2.1 Hz, J=1.2 Hz, 1H),
7.18 (d, J=1.2 Hz, 1H), 4.47 (q, J=7.2 Hz, 2H), 1.46 ppm (t, J=
7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3): d=161.8, 137.2, 131.2, 128.6,
128.5, 125.5, 121.4, 110.6, 107.2, 61.7, 14.5 ppm.
Ethyl 4,6-dichloro-1-(4-methoxybenzyl)-1H-indole-2-carbox-
ylate (13)
NaH (60% emulsion in mineral oil, 117 mg, 2.906 mmol) was added
to a solution of ethyl 1H-indole-2-carboxylate 12 (500 mg,
1.937 mmol) in DMF at 0 8C and the mixture stirred for 30 min. 4-
methoxy benzyl chloride (0.394 mL, 2.906 mmol) was then added
and the resulting mixture was stirred at ambient temperature for
16 h. Upon completion (TLC), the reaction mixture was diluted
with EtOAc and washed with water. The aqueous layer was extract-
ed with EtOAc (3V). The combined organic layer was washed with
water (3V), brine, dried over anhydrous MgSO4 and rotary evapo-
rated. The crude compound was purified by column chromatogra-
phy (ethyl acetate/n-hexane, 1:9) to afford the desired product as a
colorless solid (650 mg, 88%). 1H NMR (300 MHz, CDCl3): d=7.41
(d, J=0.9 Hz, 1H), 7.28 (d, J=1.5 Hz, 1H), 7.16 (d, J=1.5 Hz, 1H),
6.99 (td, J=8.7 Hz, J=2.1 Hz, 2H), 6.79 (td, J=8.7 Hz, J=2.1 Hz,
2H), 5.71 (s, 2H), 4.35 (q, J=7.2 Hz, 2H), 1.38 ppm (t, J=7.2 Hz,
3H). 13C NMR (75 MHz, CDCl3): d=161.9, 159.1, 139.8, 131.1, 129.4,
129.0, 128.6, 127.7, 124.0, 121.4, 114.2, 109.7, 109.4, 61.1, 55.3, 48.0,
14.4 ppm.
4,6-dichloro-1-(4-methoxybenzyl)-N-methyl-N-(prop-2-yn-1-
yl)-1H-indole-2-carboxamide (14)
A mixture of ethyl 4,6-dichloro-1-(4-methoxybenzyl)-1H-indole-2-
carboxylate 13 (600 mg, 1.586 mmol) ethyl ester, and KOH
(267 mg, 4.759 mmol) in ethanol: water (2:1, 10 mL) was heated
for 4 h at 100 8C. Upon completion (TLC), the mixture was cooled
to room temperature and evaporated in vacuo. The residue was di-
luted with water and acidified using 2m HCl. The precipitate that
was formed was filtered off and dried in vacuo to afford the de-
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sired carboxylic acid as a colorless solid (520 mg, 93%). To a solu-
tion of the carboxylic acid (500 mg, 1.428 mmol) in dichlorome-
thane (10 mL) and dimethylformamide (1 drop, cat.), oxalyl chloride
(0.184 mL, 2.142 mmol) was slowly added dropwise and stirred at
room temperature for 2 h under a nitrogen atmosphere. The sol-
vent and excess of oxalyl chloride were removed at reduced pres-
sure and the crude material dried under vacuum. To the residue,
dissolved in dry dichloromethane (10 mL) and cooled to 0 8C, a
mixture of the N-methyl propargylamine (0.181 mL, 2.142 mmol)
and triethylamine (0.595 mL, 4.283 mmol) in dry dichloromethane
(5 mL) was added dropwise. The mixture was stirred at room tem-
perature for 12 h (TLC), and evaporated. The crude residue was dis-
solved in dichloromethane (50 mL), washed with 1m HCl, saturated
NaHCO3, water, dried over anhydrous MgSO4, and concentrated in
vacuo. Purification by column chromatography on silica gel (20 to
30% EtOAc in n-hexane) provided the title compound as pale-
yellow sticky solid (30 mg, 66%). 1H NMR (300 MHz, CDCl3): d=7.30
(s, 1H), 7.15 (s, 1H), 7.01 (d, J=8.4 Hz, 2H), 6.88–6.74 (m, 3H), 5.37
(s, 2H), 4.11 (s, 2H), 3.74 (s, 3H), 3.04 (s, 3H), 2.31 ppm (s, 1H).
13C NMR (75 MHz, CDCl3): d=163.6, 159.4, 138.4, 132.5, 129.8,
129.5, 128.6, 127.8, 127.3, 124.5, 121.1, 109.4, 103.5, 78.1, 72.1, 55.5,
47.9, 39.8, 34.1 ppm.
4,6-dichloro-1-(4-methoxybenzyl)-N-methyl-N-(closo-1,2-car-
boran-1-ylmethyl)-1H-indole-2-carboxamide (15)
To a solution of nido-decaborane (38 mg, 0.306 mmol) and acetoni-
trile (0.13 mL, 2.492 mmol) in toluene (25 mL) was added 4,6-di-
chloro-1-(4-methoxybenzyl)-N-methyl-N-(prop-2-yn-1-yl)-1H-indole-
2-carboxamide 14 (100 mg, 0.249 mmol). The resulting mixture
was stirred under reflux overnight. The solvent was then removed
under reduced pressure and the residual oil was purified by
column chromatography (n-hexane-EtOAc: 100% v/v n-hexane fol-
lowed by 20% v/v EtOAc, Rf=0.45) to give the product as an off-
white solid (42 mg, 31%). 1H NMR (400 MHz, CDCl3): d=7.33–7.31
(m, 1H), 7.22 (d, J=1.2 Hz, 1H), 6.91 (d, J=8.0 Hz, 2H), 6.86–6.81
(m, 3H), 5.43 (s, 2H), 4.21 (s, 2H), 3.80 (s, 3H), 3.19(s, 3H), 2.90–
1.72 ppm (m, 10H). 13C NMR (100 MHz, CDCl3): d=164.7, 159.3,
138.5, 130.6, 130.3, 129.0, 127.7, 127.4, 123.8, 121.3, 114.3, 109.1,
104.8, 73.7, 60.3, 55.3, 53.5, 47.5, 39.6 ppm. 11B NMR (128 MHz,
CDCl3): d=@1.08 (1B), @4.89 (1B), @10.39 (2B), @12.64 ppm (6B).
ESI-MS [M+H]+ m/z 520.6 (calc. 520.5). Anal. Calcd. for
C21H28B10Cl2N2O2 : C 48.55, H 5.43, N 5.39. Found: C 48.65, H 5.71, N
5.62.
Biological assays
Radioligand binding assay
Mitochondria were prepared as previously described,[20] with minor
modifications as described below, from kidneys of male Wistar rats
killed by cervical dislocation. Kidneys were homogenized in 20 vol-
umes of ice-cold 50 mm Tris/HCl, pH 7.4, 0.32m sucrose and 1 mm
EDTA (buffer A), containing protease inhibitors (160 mgmL@1 ben-
zamidine, 200 mgmL@1 bacitracine and 20 mgmL@1 soybean tryp-
sin inhibitor) with a Teflon pestle in a glass homogenizer and cen-
trifuged at 600Vg for 10 min at 4 8C. The resulting supernatant
was centrifuged at 10000Vg for 10 min at 4 8C. The pellet was
then re-suspended in 20 volumes of ice-cold buffer A and centri-
fuged again at 10000Vg for 10 min at 4 8C. The crude mitochon-
drial pellet was frozen at @20 8C until the time of assay or incubat-
ed with 0.6 nm [3H]PK11195 in 50 mm Tris/HCl, pH 7.4 (buffer B),
with a range of concentrations of the tested compounds (0.1 nm–
10 mm) in a total volume of 0.5 mL for 90 min at 4 8C. The incuba-
tion was terminated by dilution to 5 mL with ice-cold buffer B, fol-
lowed immediately by rapid filtration through glass-fiber filters
(Whatman GF/C). The filters were then washed with buffer B
(2.5 mL) and the amount of radioactivity retained on the filters was
determined using a Packard 1600 TR liquid scintillation counter at
66% efficiency. Non-specific binding was estimated in each case in
the presence of 1 mm of unlabelled PK11195. The CC50 values were
determined and Ki values were derived according to the equation
derived previously.[21] Protein concentration was estimated by the
method of Lowry et al.[22] with bovine serum albumin (BSA) as stan-
dard.
Cell uptake studies
Human glioblastoma multiforme (T98G) cells and human glial cells
(SVGp12) were purchased from the ATCC. The cells were main-
tained as monolayers in minimum essential medium (MEM), sup-
plemented with 10% fetal bovine serum, penicillin (100 unitsmL@1),
streptomycin (100 gmL@1) and l-glutamine (2.5 mm), at 37 8C in a
humidified 5% CO2 atmosphere. Stock solutions of 10 and 15
(10 mm in DMSO) were freshly prepared. The T98G cells were sepa-
rately cultured as a monolayer in 75 cm2 flasks to 70–80% conflu-
ence then incubated with the drug-containing culture medium
(final concentration 100 mM) for 72 h at 37 8C in a humidified 5%
CO2 atmosphere. The medium was removed and the cells washed
once with PBS (2 mL). Cells were harvested by 5 min incubation
with trypsin (3 mL) followed by washing with further PBS (3 mL).
Harvested cells were pipetted to a single cell suspension then di-
vided into aliquots (100 mL) for protein analysis. The remaining
cells were sedimented by centrifugation at 2000 rpm for 3 min,
then the supernatant was removed and the cell pellet was ana-
lysed for boron content. Microwave digestion and measurement of
boron concentration by ICP-OES, according to previously estab-
lished procedures.[3] The cell pellets were transferred to pre-
cleaned TFM vessels with MQ-water (2V0.25 mL) then dried for
40 min at 100 8C in a fan forced oven and cooled to room tempera-
ture. The cell pellets were suspended in HNO3 (70%, 7.5 mL) and
H3PO4 (85%, 2.5 mL) and subjected to two high-pressure micro-
wave digestion cycles using a Milestone Ethos Plus microwave lab
station. The microwave digestion program involved heating to
200 8C over 10 min, holding for 10 min then heating to 240 8C over
5 min and sustaining this temperature for a further 20 min. Be-
tween program cycles, the closed sample vessels were cooled to
150-100 8C. At the end of the digestion process, the closed vessels
were cooled to room temperature to minimize volatile analyte
losses, and the resulting homogeneous solutions diluted with MQ-
water to a final volume of 30 mL. ICP-OES analyses were performed
in triplicate by using a PerkinElmer Optima DV7300 ICPOES at a
plasma gas flow of 15 Lmin@1, auxillary gas flow of 0.5 Lmin@1,
nebuliser gas flow of 0.7 Lmin@1 using a Burgener PEEK Mira Mist
nebuliser with cyclonic spray chamber and pump rate of
0.5 Lmin@1. Yttrium (1 ppm) was used as an internal standard by
online injection to correct for loss of analyte during sample prepa-
ration or sample inlet. Standard solutions of boric acid (0, 0.05, 0.1,
0.5, 1 and 5 ppm diluted from certified 1000 mgL@1 boric acid)
were used to prepare a calibration plot. To account for any varia-
tions in total cell number, the measured boron content was nor-
malized to cell protein measured in the corresponding cell prepa-
rations and expressed in units of mg Bmg@1 protein. The analysis of
protein content in cell pellets is described below.
Protein analyses
The bicinchoninic acid (BCA) protein assay was used to determine
protein concentration, as described previously.[3, 18] A BSA protein
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standard curve was prepared each time the assay was performed.
Lysis of cells was achieved using three snap freeze-thaw cycles and
cell debris was sedimented by centrifugation at 13300 rcf for
5 min. The supernatant solution was then analyzed for protein con-
tent by taking repeated 15 mL samples (n=3) of blank, 1 mgmL@1
BSA protein standard (200, 400, 800 and 1000 mgmL@1, made up to
volume with MQ-water) or boron-containing compound treated
protein samples and depositing these into a 96-well plate format.
Next, a freshly prepared solution of commercially-sourced BCA and
CuSO4·5H2O (50:1, 285 mL) was added to each well and the mixture
incubated at 37 8C for 45 min. Absorbance was then measured at
560 nm using an VictorX multi-wavelength plate reader (PerkinElm-
er) and protein content was determined by comparison to the BSA
standard curve.
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